Strahlentherapie und Onkologie

, Volume 194, Issue 4, pp 325–332 | Cite as

Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy

Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression
  • Gunnar Lohm
  • Konrad Neumann
  • Volker Budach
  • Thomas Wiegel
  • Stefan Hoecht
  • Johannes Gollrad
Original Article



In patients with prostate cancer (PCa) and biochemical progression (BP) after radical prostatectomy (RP), salvage radiotherapy (sRT) improves prostate cancer-specific survival (PCSS), but this evidence is based only on retrospective data.

Patients and methods

In addition to our previous study of 151 patients with PCa and BP after RP, we performed univariate analyses of prostate-specific antigen (PSA) kinetics during sRT. In 11 patients with BP or initiation of hormonal treatment (HT) within 180 days after sRT, risk factors were assessed using Mann–Whitney U tests. PSA doubling times (PSADT) before and after sRT in 82 patients with BP after sRT were compared by a Wilcoxon test.


After a median follow-up of 82 months, analysis of PSA kinetics during sRT did not show a statistically significant impact on a subsequent BP, PCSS, or overall survival at an administered dose of 30 or 45 Gy. The subgroup analysis of patients with early BP or early HT revealed higher Gleason scores (p = 0.008) and preoperative PSA values (p = 0.005), shorter PSADT prior to sRT (p < 0.0005), and longer time intervals from RP until the start of sRT (p = 0.005) compared to all other patients. In patients with subsequent BP, PSADTs were significantly prolonged after sRT (median PSADT 4.5 months before and 9.9 months after sRT, p < 0.0005).


PSA monitoring during sRT did not predict the therapeutic success. Subgroup analysis suggests a lower probability of benefit for patients with the abovenamed risk factors . However, the prolonged PSADT after sRT reflects a benefit of sRT for the vast majority of patients.


Prostate cancer specific survival Lymph node metastasis PSA doubling time Seminal vesicle involvement Androgen deprivation therapy 

Salvage-Radiotherapie bei Prostatakarzinompatienten mit biochemischem Rezidiv nach radikaler Prostatektomie

Verlängerung der Verdopplungszeit des prostataspezifischen Antigens bei Patienten mit anschließendem biochemischem Progress



Bei Patienten mit Prostatakarzinom (PCa) und biochemischer Progression (BP) nach radikaler Prostatektomie (RP) verbessert eine Salvage-Strahlentherapie (sRT) das prostatakrebsspezifische Überleben (PCSS), wobei die Evidenz hierfür lediglich auf retrospektiven Daten basiert.

Patienten und Methoden

Mit dem Datensatz unserer bereits veröffentlichten Studie zur sRT von 151 Patienten mit BP nach RP führten wir zusätzliche Analysen zum Verlauf des prostataspezifischen Antigens (PSA) während der sRT durch. Insgesamt 11 Patienten mit BP oder Beginn einer Hormontherapie (HT) innerhalb von 180 Tagen nach sRT wurden mittels Mann-Whitney-U-Tests auf Risikofaktoren untersucht. Mit dem Wilcoxon-Test wurden die PSA-Verdopplungszeiten (PSADT) vor und nach sRT bei 82 Patienten mit erneutem BP nach sRT verglichen.


Nach einer medianen Nachbeobachtungszeit von 82 Monaten ergab die Analyse des PSA-Verlaufs während sRT nach Strahlendosen von 30 bzw. 45 Gy keinen statistisch signifikanten Einfluss, weder auf einen weiteren BP, noch auf das PCSS bzw. das Gesamtüberleben. Patienten mit frühem BP oder HT-Beginn hatten im Vergleich zu den übrigen Patienten signifikant höhere Gleason-Scores (p = 0,008), höhere PSA-Werte vor RP (p = 0,005), kürzere PSADT vor Beginn der sRT (p < 0,0005) und längere Zeitintervalle von RP bis zum sRT-Beginn (p = 0,005). Bei Patienten mit erneutem BP war die PSADT nach sRT signifikant verlängert (mediane PSADT 4,5 Monate vor und 9,9 Monate nach sRT; p < 0,0005).


Der weitere Krankheitsverlauf ließ sich durch PSA-Monitoring während der sRT nicht vorhersagen. Weniger erfolgsversprechend erscheint die sRT für Patienten mit den Risikofaktoren, die in der Subgruppenanalyse gefunden wurden. Die verlängerte PSADT nach sRT zeigt hingegen einen Vorteil dieser Behandlung für die überwältigende Mehrheit der Patienten an.


Prostatakrebs-spezifisches Überleben Lymphknotenbefall PSA-Verdopplungszeit Samenblasenbefall Androgenentzugstherapie 


Compliance with ethical guidelines

Conflict of interest

G. Lohm, K. Neumann, V. Budach, T. Wiegel, S. Hoecht, and J. Gollrad declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597CrossRefPubMedGoogle Scholar
  2. 2.
    Lohm G, Lutcke J, Jamil B, Hocht S, Neumann K, Hinkelbein W et al (2014) Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy: long-term follow-up of a single-center survey. Strahlenther Onkol 190:727–731CrossRefPubMedGoogle Scholar
  3. 3.
    Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M et al (2014) A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy—Adjuvant Versus Early Salvage (RAVES) trial. BJU Int 113(Suppl 2):7–12CrossRefPubMedGoogle Scholar
  5. 5.
    Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C et al (2007) Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 99:1376–1379CrossRefPubMedGoogle Scholar
  6. 6.
    Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027CrossRefPubMedGoogle Scholar
  7. 7.
    Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66:243–250CrossRefPubMedGoogle Scholar
  8. 8.
    Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Holscher T, Gut P et al (2015) Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 33:4158–4166CrossRefPubMedGoogle Scholar
  10. 10.
    Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17:747–756CrossRefPubMedGoogle Scholar
  11. 11.
    Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417–428CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A et al (2009) Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome—results of a retrospective study. Int J Radiat Oncol Biol Phys 73:1009–1016CrossRefPubMedGoogle Scholar
  13. 13.
    Do T, Dave G, Parker R, Kagan AR (2001) Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes. Int J Radiat Oncol Biol Phys 50:1220–1225CrossRefPubMedGoogle Scholar
  14. 14.
    Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP et al (2014) Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. Pract Radiat Oncol 4:409–414CrossRefPubMedGoogle Scholar
  15. 15.
    Budaus L, Schiffmann J, Graefen M, Huland H, Tennstedt P, Siegmann A et al (2017) Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy: informing the debate. Strahlenther Onkol. PubMedGoogle Scholar
  16. 16.
    Ohri N, Dicker AP, Trabulsi EJ, Showalter TN (2012) Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 48:837–844CrossRefPubMedGoogle Scholar
  17. 17.
    King CR (2012) The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 84:104–111CrossRefPubMedGoogle Scholar
  18. 18.
    Lohm G, Bottke D, Jamil B, Miller K, Neumann K, Bartkowiak D et al (2013) Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. World J Urol 31:423–428CrossRefPubMedGoogle Scholar
  19. 19.
    Moghanaki D, Koontz BF, Karlin JD, Wan W, Mukhopadhay N, Hagan MP et al (2013) Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. Cancer 119:52–60CrossRefPubMedGoogle Scholar
  20. 20.
    Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P et al (2017) Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. Eur Urol 72(5):689–709. CrossRefPubMedGoogle Scholar
  21. 21.
    Bernard JR Jr., Buskirk SJ, Heckman MG, Diehl NN, Ko SJ, Macdonald OK et al (2010) Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 76:735–740CrossRefPubMedGoogle Scholar
  22. 22.
    Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA et al (2016) Salvage radiation therapy dose response for biochemical failure of prostate cancer after prostatectomy—a multi-institutional observational study. Int J Radiat Oncol Biol Phys 96:1046–1053CrossRefPubMedGoogle Scholar
  23. 23.
    Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B et al (2016) The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 118(Suppl 3):49–55CrossRefPubMedGoogle Scholar
  24. 24.
    Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive 68 Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRefPubMedGoogle Scholar
  25. 25.
    Zdrojowy R, Dembowski J, Malkiewicz B, Tupikowski K, Krajewski W (2016) Salvage local therapy for radiation-recurrent prostate cancer—where are we? Cent European J Urol 69:264–270PubMedPubMedCentralGoogle Scholar
  26. 26.
    Buchser D, Gomez-Iturriaga A, Melcon JI, Casquero F, Llarena R, Cacicedo J et al (2016) Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. J Contemp Brachytherapy 8:477–483CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Teeter AE, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL et al (2009) Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int 104:1604–1609CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Gunnar Lohm
    • 1
  • Konrad Neumann
    • 2
  • Volker Budach
    • 1
  • Thomas Wiegel
    • 3
  • Stefan Hoecht
    • 4
  • Johannes Gollrad
    • 1
  1. 1.Department of Radiation OncologyCharité UniversitätsmedizinBerlinGermany
  2. 2.Department of Biometry and Clinical EpidemiologyCharité UniversitätsmedizinBerlinGermany
  3. 3.Department of Radiation OncologyUniversity Hospital UlmUlmGermany
  4. 4.Xcare Praxis für StrahlentherapieSaarlouisGermany

Personalised recommendations